CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A...Nanobiotix S.A. • April 24th, 2023 • Pharmaceutical preparations
TO AMENDED AND RESTATED STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • April 24th, 2023 • Nanobiotix S.A. • Pharmaceutical preparations
This Amendment No. 1 (“Amendment”) is entered into as of June 4, 2021 (“Amendment No. 1 Effective Date”) by and between The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030, USA (“MD Anderson”), a member institution of The University of Texas System (“UT System”) and Nanobiotix S.A., with a place of business located at 60 Rue de Wattignies, 75012 Paris, France Nanobiotix (“Nanobiotix”) (MD Anderson and Nanobiotix each a “Party” and collectively the “Parties”).
CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A...Royalty Agreement • April 24th, 2023 • Nanobiotix S.A. • Pharmaceutical preparations
Dated 18 October 2022 Contract number (FI No): 89427Contract number (FI No): 89987Serapis No: 2018-0245 European Investment Bank(the Bank) - and - Nanobiotix(the Company) Amendment Agreement relating to a Royalty agreementdated 26 July 2018 1M0186.000509PARLIB01/SALEMALE/4153-5782-9692
